.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XX11_Tedizolid.Tedizolid

Information

Tedizolid is an oxazolidinone-class antibacterial agent, primarily used for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). It is approved for use in adults and adolescents.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers after administration of tedizolid phosphate 200 mg orally once daily.

References

1. Flanagan, S, et al., & Prokocimer, P (2014). Tedizolid population pharmacokinetics, exposure response, and target attainment. Antimicrobial agents and chemotherapy 58(11) 6462–6470. DOI:10.1128/AAC.03423-14 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25136028

2. Li, D, et al., & Rizk, ML (2021). Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections. Antimicrobial agents and chemotherapy 65(12) e0089521–None. DOI:10.1128/AAC.00895-21 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34516243

3. Park, AYJ, et al., & Beringer, PM (2018). Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis. Antimicrobial agents and chemotherapy 62(9) –. DOI:10.1128/AAC.00550-18 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29914949

Revisions

• 06/2025 initial generated model